Business Context and Reporting Period
This Form 8-K Current Report was filed by Neurocrine Biosciences, Inc. on May 30, 2025. The filing discloses a leadership transition within the company's executive management team, specifically regarding the Chief Medical Officer position.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Executive Transition: Sanjay Keswani, M.D. is scheduled to succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025.
- Role Change: Dr. Roberts will transition from Chief Medical Officer to a Strategic Advisor to the CEO role.
- Compensation Agreement: An Amended and Restated Employment Agreement was executed on May 30, 2025, effective upon the transition date.
Management Commentary and Compensation Details
Dr. Roberts, who served as Chief Medical Officer for seven years, will serve as Strategic Advisor through December 31, 2025. Under the new agreement:
- Base Salary: Annual base salary remains at $731,400.
- Bonus: Eligible for an annual cash incentive bonus with a target of 60% of base pay for calendar year 2025.
- Severance: Substantially the same severance benefits as previously eligible under the Executive Severance Plan adopted on February 7, 2025.
- Equity: Outstanding equity awards will remain outstanding and continue to vest according to their existing terms.
Investor Verification Checklist
- Verify the exact commencement date of Dr. Keswani's employment to confirm the "Transition Date."
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) for complete terms.
- Confirm the vesting schedules of Dr. Roberts' outstanding equity awards.
- Monitor future filings for any additional changes to the executive team or strategic direction.